
Pei Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/773837/publications.pdf Version: 2024-02-01



DELLII

#	Article	IF	CITATIONS
1	Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 2024-2032.	13.7	338
2	Circular RNA DLGAP4 Ameliorates Ischemic Stroke Outcomes by Targeting miR-143 to Regulate Endothelial-Mesenchymal Transition Associated with Blood–Brain Barrier Integrity. Journal of Neuroscience, 2018, 38, 32-50.	3.6	306
3	Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet, The, 2015, 385, 2272-2279.	13.7	149
4	CircDYM ameliorates depressive-like behavior by targeting miR-9 to regulate microglial activation via HSP90 ubiquitination. Molecular Psychiatry, 2020, 25, 1175-1190.	7.9	108
5	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Global Health, 2017, 5, e324-e334.	6.3	85
6	Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet, The, 2013, 381, 1037-1045.	13.7	76
7	Dietary intake of lead and cadmium by children and adults – Result calculated from dietary recall and available lead/cadmium level in food in comparison to result from food duplicate diet method. International Journal of Hygiene and Environmental Health, 2010, 213, 450-457.	4.3	69
8	2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. Journal of Infectious Diseases, 2017, 215, 56-63.	4.0	52
9	Food safety risk assessment in China: Past, present and future. Food Control, 2018, 90, 212-221.	5.5	52
10	Blended learning with Moodle in medical statistics: an assessment of knowledge, attitudes and practices relating to e-learning. BMC Medical Education, 2017, 17, 170.	2.4	31
11	Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Human Vaccines and Immunotherapeutics, 2017, 13, 2078-2085.	3.3	28
12	A Meta-Analysis of the Association between ESR1 Genetic Variants and the Risk of Breast Cancer. PLoS ONE, 2016, 11, e0153314.	2.5	24
13	Healthcare system responsiveness in Jiangsu Province, China. BMC Health Services Research, 2017, 17, 31.	2.2	21
14	Human health risk assessment of cadmium via dietary intake by children in Jiangsu Province, China. Environmental Geochemistry and Health, 2017, 39, 29-41.	3.4	18
15	Dietary intake of mercury by children and adults in Jinhu area of China. International Journal of Hygiene and Environmental Health, 2011, 214, 246-250.	4.3	17
16	Comparison of Accelerated and Standard Hepatitis B Vaccination Schedules in High-Risk Healthy Adults: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0133464.	2.5	16
17	Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China. BMC Health Services Research, 2013, 13, 386.	2.2	15
18	Dietary exposure and risk assessment to lead of the population of Jiangsu province, China. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2014, 31, 1-9.	2.3	15

Pei Liu

#	Article	IF	CITATIONS
19	Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine. Scientific Reports, 2015, 5, 14660.	3.3	15
20	Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2015, 11, 1418-1425.	3.3	15
21	Viral hepatitis vaccination during pregnancy. Human Vaccines and Immunotherapeutics, 2016, 12, 894-902.	3.3	15
22	Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Review of Vaccines, 2017, 16, 945-949.	4.4	15
23	Comparison between EQ-5D and SF-6D Utility in Rural Residents of Jiangsu Province, China. PLoS ONE, 2012, 7, e41550.	2.5	14
24	Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials. BMC Pediatrics, 2014, 14, 307.	1.7	14
25	Longâ€ŧerm effect of interferon treatment on the progression of chronic hepatitis B: Bayesian metaâ€∎nalysis and metaâ€ŧegression. Hepatology Research, 2011, 41, 512-523.	3.4	13
26	Direct Economic Burden and Influencing Factors in Patients With Hepatitis B Virus Related Diseases in Jiangsu, China. Asia-Pacific Journal of Public Health, 2015, 27, 41S-48S.	1.0	12
27	Comparison of Two Bayesian Methods in Evaluation of the Absence of the Gold Standard Diagnostic Tests. BioMed Research International, 2019, 2019, 1-9.	1.9	12
28	A systematic review on food lead concentration and dietary lead exposure in China. Chinese Medical Journal, 2014, 127, 2844-9.	2.3	11
29	The false-positive and false-negative predictive value of HIV antibody test in the Chinese population. Journal of Medical Screening, 2008, 15, 72-75.	2.3	9
30	Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Review of Vaccines, 2017, 16, 1155-1169.	4.4	8
31	The long-term effect of community-based health management on the elderly with type 2 diabetes by the Markov modeling. Archives of Gerontology and Geriatrics, 2014, 59, 353-359.	3.0	7
32	Maximum cadmium limits establishment strategy based on the dietary exposure estimation: an example from Chinese populations and subgroups. Environmental Science and Pollution Research, 2018, 25, 18762-18771.	5.3	7
33	The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review. Human Vaccines and Immunotherapeutics, 2021, 17, 880-896.	3.3	7
34	Dietary exposure and risk assessment to cadmium of the adult population of Jiangsu province, China: Comparing between semi-probabilistic and fully probabilistic approaches. Human and Ecological Risk Assessment (HERA), 2016, 22, 226-240.	3.4	6
35	Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11.	3.3	5
36	Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints. Human Vaccines and Immunotherapeutics, 2019, 15, 256-263.	3.3	4

Pei Liu

#	Article	IF	CITATIONS
37	Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PLoS ONE, 2016, 11, e0161936.	2.5	4
38	Evaluation of 30 commercial assays for the detection of antibodies to HIV in China using classical and Bayesian statistics. Journal of Virological Methods, 2010, 170, 73-79.	2.1	3
39	Bayesian evaluation of the human immunodeficiency virus antibody screening strategy of duplicate enzymeâ€linked immunosorbent assay in Xuzhou Blood Center, China. Transfusion, 2011, 51, 793-798.	1.6	3
40	Estimation of the sensitivity and specificity of assays for screening antibodies to HIV: A comparison between the frequentist and Bayesian approaches. Journal of Virological Methods, 2012, 186, 89-93.	2.1	3
41	The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months. Expert Review of Vaccines, 2017, 16, 515-524.	4.4	3
42	Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeqâ"¢) postlicensure: a meta-analysis—2006–2020. Expert Review of Vaccines, 2021, 20, 1-12.	4.4	2
43	The Impact of Health Insurance on Economic Burden for Hepatitis B Inpatients in China. Iranian Journal of Public Health, 2016, 45, 107-8.	0.5	2
44	Co-localization of circDYM with miR-9 in microglia. Molecular Psychiatry, 2020, 25, 1155-1155.	7.9	1
45	Health Care Utilization and Costs in Patients with Hepatitis B related Disease in Jiangsu, China. Iranian Journal of Public Health, 2015, 44, 297-8.	0.5	1
46	Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
47	Willing to Pay for Antiviral Treatment of Hepatitis B Patients. Iranian Journal of Public Health, 2016, 45, 1660-1661.	0.5	Ο
48	Time Series Analysis in Modeling of Hepatitis B Incidence. Iranian Journal of Public Health, 2019, 48, 554-555.	0.5	0